These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1326 related articles for article (PubMed ID: 16301343)

  • 1. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
    Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
    Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
    N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Reed SD; McMurray JJ; Velazquez EJ; Schulman KA; Califf RM; Kober L; Maggioni AP; Van de Werf F; White HD; Diaz R; Mareev V; Murin J;
    Am Heart J; 2006 Sep; 152(3):500-8. PubMed ID: 16923421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
    Thomas KL; Al-Khatib SM; Lokhnygina Y; Solomon SD; Kober L; McMurray JJ; Califf RM; Velazquez EJ
    Am Heart J; 2008 Jan; 155(1):87-93. PubMed ID: 18082495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
    Shamshad F; Kenchaiah S; Finn PV; Soler-Soler J; McMurray JJ; Velazquez EJ; Maggioni AP; Califf RM; Swedberg K; Kober L; Belenkov Y; Varshavsky S; Pfeffer MA; Solomon SD;
    Am Heart J; 2010 Jul; 160(1):145-51. PubMed ID: 20598985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
    J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
    Moukarbel GV; Signorovitch JE; Pfeffer MA; McMurray JJ; White HD; Maggioni AP; Velazquez EJ; Califf RM; Scheiman JM; Solomon SD
    Eur Heart J; 2009 Sep; 30(18):2226-32. PubMed ID: 19556260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
    Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
    Thune JJ; Signorovitch JE; Kober L; McMurray JJ; Swedberg K; Rouleau J; Maggioni A; Velazquez E; Califf R; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2011 Feb; 13(2):148-53. PubMed ID: 21037250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.